Jeol (6951) · FactRestated
Competitive advantages of medical equipment in reagent and specimen usage and running costs
First written in FY2018. 1 of 2 entries say "Restated". Latest entry: FY2019.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Strengthening price and cost competitiveness in the medical device businessA theme 2 companies write about · 0 as a headwind · 2 as a tailwind
1 other company's latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2019RestatedAnnual report
「The low reagent and specimen requirements and running-cost advantage of the Company’s products remain competitive advantages.」
The continued disclosure identifies low reagent and specimen usage and low running costs as competitive advantages of the medical equipment. - FY2018First statedAnnual report
「Our products continue to have a competitive advantage due to their low reagent and specimen usage and their advantage in running costs. Sales of biochemical automated analyzers for the domestic market and immunoassay systems supplied to Fujirebio as an OEM customer remained strong.」
The Company describes the low usage of reagents and specimens and the advantage in running costs as competitive strengths of its medical equipment.